(MENAFN - ProactiveInvestors - Australia) EcoQuest (ASX: ECQ) has increased its investment in U.S.-based emerging biotechnology company Cynata Incorporated taking its interest in the company to 29%.
The company has entered into an agreement to acquire a further 18% of the issued capital of Cynata Incorporated, which specialises in multi-purpose stem cell technology for regenerative medicine.
EcoQuest has subscribed for 12.5 million shares at US0.04 each, for a total consideration of US500,000.
EcoQuest previously held an 11% interest in Cynata, which was formed to commercialise stem cell technology from the University of Wisconsin-Madison.
Cynata's plan is develop the technology into an "off-the-shelf" therapeutic stem cell platform to be used in therapeutic products.
The cells stimulate the formation of new blood vessels in damaged tissue, and as a result have great potential to treat diseases requiring revascularisation.
Cynata's initial focus is on critical limb ischemia, a severe consequence of diabetes, causing severe pain, ulcers, and gangrene.
The regenerative medicine market represents a major growth segment.
Through its investment in Cynata, EcoQuest will gain exposure to a 3 billion market opportunity focused on the complications of diabetes alone.
Further development will target other complications of diabetes, other indications involving a loss of circulation or damaged blood vessels and Graft versus Host disease. These conditions represent a market worth over 10 billion.